MoonLake Immunotherapeutics(MLTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MLTX MoonLake Immunotherapeutics

休市中 02-20 16:00:00 EST

18.77

+0.60

+3.30%

盘后18.77

+0.00-0.01%

19:59 EST

最高18.80	最低17.32	成交量198.29万
今开17.98	昨收18.17	日振幅8.15%
总市值13.40亿	流通市值7.59亿	总股本7,137万
成交额3,640万	换手率4.91%	流通股本4,042万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":18.77,"timestamp":1771621200000,"preClose":18.17,"halted":0,"volume":1982862,"hourTrading":{"tag":"盘后","latestPrice":18.7684,"preClose":18.77,"latestTime":"19:59 EST","volume":54009,"amount":1011341.2873,"timestamp":1771635565287,"change":-0.0016,"changeRate":-0.000085,"amplitude":0.020384},"delay":0,"changeRate":0.0330214639515684,"floatShares":40415700,"shares":71373579,"eps":-3.328528,"marketStatus":"休市中","change":0.6,"latestTime":"02-20 16:00:00 EST","open":17.98,"high":18.8,"low":17.32,"amount":36398570.880546,"amplitude":0.081453,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.328528,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":18.17,"preHourTrading":{"tag":"盘前","latestPrice":17.96,"preClose":18.17,"latestTime":"09:26 EST","volume":1662,"amount":29757.403650000004,"timestamp":1771597610055,"change":-0.21,"changeRate":-0.011558,"amplitude":0.036324},"postHourTrading":{"tag":"盘后","latestPrice":18.7684,"preClose":18.77,"latestTime":"19:59 EST","volume":54009,"amount":1011341.2873,"timestamp":1771635565287,"change":-0.0016,"changeRate":-0.000085,"amplitude":0.020384},"volumeRatio":1.1724438689403913,"impliedVol":0.961,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/MLTX","defaultTab":"news","newsList":[{"id":"1177588141","title":"MoonLake公布Sonelokimab治疗中轴型脊柱关节炎二期临床试验积极顶线结果及2025年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1177588141","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177588141?lang=zh_cn&edition=full","pubTime":"2026-02-23 00:01","pubTimestamp":1771776073,"startTime":"0","endTime":"0","summary":"生物技术公司MoonLake Immunotherapeutics宣布，其创新药物Sonelokimab针对中轴型脊柱关节炎的二期临床试验取得积极顶线结果。该试验数据显示，Sonelokimab在主要疗效终点上表现出显著优势，为患者提供了新的治疗希望。\n同时，公司披露了2025年度财务报告，核心财务指标稳健，研发投入持续加大，为后续临床推进提供资金保障。此次成果标志着MoonLake在免疫疗法领域取得重要突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"1101490562","title":"MoonLake获FDA快速通道认定 用于sonelokimab治疗掌跖脓疱病 并公布投资者日活动细节","url":"https://stock-news.laohu8.com/highlight/detail?id=1101490562","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101490562?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:01","pubTimestamp":1770037285,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics（纳斯达克代码：MLTX）宣布，其候选药物sonelokimab用于治疗掌跖脓疱病（PPP）已获得美国食品药品监督管理局（FDA）的快速通道资格认定。\n此次认定将有助于加速该药物的开发和审评进程，为患有这一慢性、衰弱性皮肤病的患者带来新的治疗希望。掌跖脓疱病是一种罕见的炎症性皮肤病，目前治疗选择有限。\n同时，公司公布了即将举行的投资者日的详细安排。此次活动将向投资者和分析师深入介绍公司的研发管线、战略规划以及sonelokimab的最新临床进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2603569676","title":"Moonlake Immunotherapeutics盘中异动 快速下跌5.04%报17.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603569676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603569676?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:16","pubTimestamp":1768317374,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日23时16分，Moonlake Immunotherapeutics股票出现异动，股价快速跳水5.04%。截至发稿，该股报17.18美元/股，成交量34.0294万股，换手率0.48%，振幅5.42%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体跌幅为0.49%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家处于临床阶段的生物技术公司，致力于推进治疗方案以满足炎症性皮肤和关节疾病领域的未满足需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113231614a4bf6c0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113231614a4bf6c0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"1101897036","title":"FDA确认MoonLake的HS药物无需额外试验即可获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1101897036","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101897036?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:40","pubTimestamp":1767879602,"startTime":"0","endTime":"0","summary":"1月8日，MoonLake盘前一度飙涨50%！公司宣布FDA反馈确认其无需开展额外临床试验，即可为化脓性汗腺炎适应症积累充分的疗效证据。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"33791b051befbfd8525af904615f530c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"FDA确认MoonLake的HS药物无需额外试验即可获批","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX"],"gpt_icon":1},{"id":"1197700111","title":"MoonLake Immunotherapeutics 与美国 FDA 会面讨论皮肤病药物上市申请后 盘前股价飙升35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197700111","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197700111?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:23","pubTimestamp":1767878599,"startTime":"0","endTime":"0","summary":"在宣布与美国食品药品监督管理局（FDA）就公司皮肤病治疗药物的营销申请进行会面后，MoonLake Immunotherapeutics 的股价在盘前交易时段大幅上涨35%。\n此次会议主要围绕其皮肤病药物的上市申请展开讨论，市场对此反应极为积极。投资者情绪受到显著提振，显示出对该药物获批前景的强烈信心。股价的强劲表现反映了市场对此次监管沟通成果的乐观解读。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"33791b051befbfd8525af904615f530c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"1138344537","title":"异动解读 | MoonLake Immunotherapeutics盘前大涨43.58%，FDA会议积极成果及投资者日活动提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1138344537","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138344537?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:14","pubTimestamp":1767878080,"startTime":"0","endTime":"0","summary":"生物技术公司MoonLake Immunotherapeutics（MLTX）今日盘前股价大幅上涨43.58%，创下显著涨幅。消息面上，公司宣布与美国食品药品监督管理局（FDA）的B类会议取得积极成果，标志着其研发管线的重要进展。这一进展为后续开发路径提供了明确指引，增强了市场对公司未来发展的信心。此外，MoonLake Immunotherapeutics还宣布将举办投资者日活动，旨在向投资界详细介绍公司的最新发展、战略规划及未来展望。这一举措进一步强化了公司与市场的沟通，为股价上涨提供了额外支撑。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"33791b051befbfd8525af904615f530c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MLTX"],"gpt_icon":0},{"id":"1131151329","title":"MoonLake Immunotherapeutics与美国FDA达成B类会议积极成果，并宣布投资者日活动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131151329","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131151329?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:02","pubTimestamp":1767877370,"startTime":"0","endTime":"0","summary":"生物技术公司MoonLake Immunotherapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的B类会议取得了积极成果。此次建设性对话标志着公司研发管线的重要进展，为后续开发路径提供了明确指引。\n与此同时，公司正式宣布将举办投资者日活动。该活动旨在向投资界深入介绍公司的最新发展、战略规划及未来展望，进一步加强市场沟通。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"33791b051befbfd8525af904615f530c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"1180289183","title":"MoonLake Immunotherapeutics发布2025年第三季度财务成绩，并公布Nanobody® Sonelokimab临床试验的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1180289183","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180289183?lang=zh_cn&edition=full","pubTime":"2025-11-05 20:00","pubTimestamp":1762344014,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics发布2025年第三季度财务成绩，并公布Nanobody® Sonelokimab临床试验的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2572568440","title":"Moonlake Immunotherapeutics盘中异动 早盘急速上涨5.09%报7.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572568440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572568440?lang=zh_cn&edition=full","pubTime":"2025-10-03 21:32","pubTimestamp":1759498334,"startTime":"0","endTime":"0","summary":"北京时间2025年10月03日21时32分，Moonlake Immunotherapeutics股票出现波动，股价急速拉升5.09%。截至发稿，该股报7.84美元/股，成交量79.2662万股，换手率1.25%，振幅4.29%。Moonlake Immunotherapeutics股票所在的生物技术行业中，整体涨幅为0.33%。Moonlake Immunotherapeutics公司简介：MoonLake Immunotherapeutics 是一家处于临床阶段的生物技术公司，致力于推进治疗方案以满足炎症性皮肤和关节疾病领域的未满足需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100321321494b9cd8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100321321494b9cd8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MLTX","BK4139"],"gpt_icon":1},{"id":"1135869367","title":"MoonLake Immunotherapeutics管理人员Chen Bihua减持6509428股","url":"https://stock-news.laohu8.com/highlight/detail?id=1135869367","media":"老虎公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135869367?lang=zh_cn&edition=full","pubTime":"2025-10-02 05:25","pubTimestamp":1759353925,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics的10%股东兼管理人员Chen Bihua于2025年9月29日至9月30日期间，进行了一系列的股票出售操作，累计出售6,509,428股Class A普通股。此类大规模的持股减少可能对投资者传递出公司增长潜力有限的信号，需密切关注公司未来发展以及市场对此回应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MoonLake Immunotherapeutics管理人员Chen Bihua减持6509428股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX"],"gpt_icon":0},{"id":"1103546567","title":"异动解读 | MoonLake Immunotherapeutics股价暴跌90%，关键药物临床试验结果不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1103546567","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103546567?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:00","pubTimestamp":1759176035,"startTime":"0","endTime":"0","summary":"周一盘中，生物制药公司MoonLake Immunotherapeutics股价遭遇重创，暴跌90.36%，创下历史性跌幅。这一罕见的大幅下跌主要源于公司最新公布的临床试验结果不及预期，以及随之而来的分析师评级下调。MoonLake Immunotherapeutics公布了其Vela三期临床项目的第16周试验结果，该项目评估纳米抗体Sonelokimab在治疗中重度化脓性汗腺炎方面的疗效。对MoonLake而言，这次临床试验结果不佳可能严重影响其在竞争激烈的化脓性汗腺炎治疗市场中的地位，并可能对公司的长期发展前景产生重大影响。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"557aa002696a37badb925380bebef243","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MLTX"],"gpt_icon":1},{"id":"1121188408","title":"MoonLake Immunotherapeutics股价跌至三年多来新低 皮肤病药物后期试验数据公布后暴跌89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188408","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121188408?lang=zh_cn&edition=full","pubTime":"2025-09-29 21:35","pubTimestamp":1759152934,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics股价跌至三年多来新低，此前该公司公布了其皮肤病药物的后期阶段试验数据，股价最后下跌89%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"557aa002696a37badb925380bebef243","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"1103845256","title":"异动解读 | MoonLake Immunotherapeutics股价盘中暴跌88.77%，临床试验结果不及预期且遭遇评级下调","url":"https://stock-news.laohu8.com/highlight/detail?id=1103845256","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103845256?lang=zh_cn&edition=full","pubTime":"2025-09-29 21:32","pubTimestamp":1759152742,"startTime":"0","endTime":"0","summary":"生物制药公司MoonLake Immunotherapeutics周一盘中股价暴跌88.77%，创下历史性跌幅。这一罕见的大幅下跌主要源于两个重要因素：公司最新临床试验结果不及预期，以及分析师大幅下调评级。首先，MoonLake Immunotherapeutics公布了其Vela三期临床项目的第16周试验结果，该项目正在评估纳米抗体Sonelokimab在治疗中重度化脓性汗腺炎方面的疗效。这一结果严重打击了投资者对MoonLake前景的信心。\"这两个因素叠加，导致MLTX股价在盘中交易中遭遇近乎腰斩的暴跌，引发市场广泛关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"557aa002696a37badb925380bebef243","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MLTX"],"gpt_icon":0},{"id":"1159375955","title":"MoonLake Immunotherapeutics股价盘前暴跌87.2% 皮肤病药物后期临床数据公布后","url":"https://stock-news.laohu8.com/highlight/detail?id=1159375955","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159375955?lang=zh_cn&edition=full","pubTime":"2025-09-29 18:48","pubTimestamp":1759142893,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics股价盘前暴跌87.2%，此前该公司公布了其皮肤病治疗药物的后期临床试验数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"557aa002696a37badb925380bebef243","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2571849603","title":"MoonLake关键药物临床数据不及预期，并遭大行下调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2571849603","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571849603?lang=zh_cn&edition=full","pubTime":"2025-09-29 18:32","pubTimestamp":1759141934,"startTime":"0","endTime":"0","summary":"最新消息将成为投资者的一次重大清算事件。","market":"us","thumbnail":"https://static.tigerbbs.com/b3d8232a60f44cfcd0c7bfde85fd86a1","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b3d8232a60f44cfcd0c7bfde85fd86a1"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"557aa002696a37badb925380bebef243","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350699.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MoonLake关键药物临床数据不及预期，并遭大行下调评级","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MLTX"],"gpt_icon":1},{"id":"1121950852","title":"异动解读 | MoonLake Immunotherapeutics盘前暴跌86%，遭遇评级下调及临床试验结果不佳双重打击","url":"https://stock-news.laohu8.com/highlight/detail?id=1121950852","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121950852?lang=zh_cn&edition=full","pubTime":"2025-09-29 16:40","pubTimestamp":1759135230,"startTime":"0","endTime":"0","summary":"周一盘前，生物制药公司MoonLake Immunotherapeutics股价暴跌86.24%，引起市场广泛关注。这一罕见的大幅下跌主要源于两个重要因素。RBC将MLTX的投资评级从\"跑赢大盘\"下调至\"板块表现\"，同时将目标价从67美元大幅下调至10美元，降幅高达85%。这一举动严重打击了投资者信心，导致股价大幅下挫。其次，公司最新发布的临床试验结果令人失望。这两个因素叠加，导致MLTX股价在盘前交易中遭遇近乎腰斩的暴跌。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"557aa002696a37badb925380bebef243","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MLTX"],"gpt_icon":0},{"id":"1144642467","title":"异动解读 | MoonLake Immunotherapeutics盘前暴跌86.24%，临床试验结果和评级下调双重打击","url":"https://stock-news.laohu8.com/highlight/detail?id=1144642467","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144642467?lang=zh_cn&edition=full","pubTime":"2025-09-29 16:40","pubTimestamp":1759135228,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics今日盘前股价暴跌86.24%，引起市场广泛关注。这一大幅下跌主要源于两个因素：公司最新临床试验结果的发布以及分析师的评级下调。首先，MoonLake Immunotherapeutics公布了其Vela三期化脓性汗腺炎临床项目的第16周试验结果。虽然具体结果尚未详细披露，但市场对此反应强烈，暗示结果可能不及预期。其次，加拿大皇家银行大幅调整了对MoonLake Immunotherapeutics的评级。RBC将公司的投资评级从\"跑赢大盘\"下调至\"板块表现\"，同时大幅下调目标价，从此前的67美元降至10美元。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"557aa002696a37badb925380bebef243","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MLTX"],"gpt_icon":0},{"id":"1173987934","title":"MoonLake Immunotherapeutics获RBC下调评级至\"板块表现\"并大幅下调目标价至10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173987934","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173987934?lang=zh_cn&edition=full","pubTime":"2025-09-29 12:34","pubTimestamp":1759120457,"startTime":"0","endTime":"0","summary":"加拿大皇家银行(RBC)将MoonLake Immunotherapeutics的投资评级从\"跑赢大盘\"下调至\"板块表现\"，同时大幅下调目标价，从此前的67美元降至10美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"1192881400","title":"美股夜盘 | 加密货币股普涨，BitMine涨超5%；英伟达概念股反弹，APLD涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192881400","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192881400?lang=zh_cn&edition=full","pubTime":"2025-09-29 08:05","pubTimestamp":1759104305,"startTime":"0","endTime":"0","summary":"9月29日，美股夜盘时段，加密货币股普涨，$BitMine$涨超5%，$SharpLink Gaming$、$MARA Holdings$涨超3%，$CleanSpark$、$Coinbase$、$Strategy$涨超2%，$Hut 8$、$Circle$涨超1%。比特币重回11.2万美元上方，以太坊突破4100美元关口。部分英伟达概念股反弹， $APPLIED DIGITAL CORP$， $CoreWeave, Inc.$，$NEBIUS$均涨超1%。$MoonLake Immunotherapeutics$夜盘大跌近19%，公司发布了其Vela三期化脓性汗腺炎临床项目的第16周试验结果，该项目正在评估纳米抗体Sonelokimab的疗效。","market":"us","thumbnail":"https://static.tigerbbs.com/4f6ec6e99c0c8b9feb7f296b78c65a54","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/4f6ec6e99c0c8b9feb7f296b78c65a54"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"129c130731f03604bb6c431bd4870b73","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4596","BK4147","BK4527","BK4533","BK4150","BK4598","BK4587","BK4554","BK4567","BK4588","BK4139","BK4516","BK4543","BK4077","BK4550","BK4535","BK4097","BK4529","BK4612",".IXIC","BK4608","BK4581","BK4614","BK4551","BK4534","BK4116",".DJI","BK4592","BK4548","BK4503","BMNR","BK4023","BK4579","BK4532","BK4609","BK4141",".SPX","BK4585","BK4600","BK4539","MLTX","BK4547","BK4605","BK4595","BK4549"],"gpt_icon":0},{"id":"1106728172","title":"MoonLake Immunotherapeutics - Sonelokimab在Vela试验中所有主要及关键次要终点均显示显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1106728172","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106728172?lang=zh_cn&edition=full","pubTime":"2025-09-29 00:08","pubTimestamp":1759075695,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics - Sonelokimab在Vela试验中所有主要及关键次要终点均显示显著改善","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":0.1902},{"period":"1month","weight":0.1233},{"period":"3month","weight":0.4815},{"period":"6month","weight":-0.6642},{"period":"1year","weight":-0.5542},{"period":"ytd","weight":0.4241}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MoonLake Immunotherapeutics是一家于2020年8月13日注册的开曼群岛公司，该公司是一家临床阶段的生物技术公司，致力于推进变革性疗法，以解决炎症性皮肤和关节疾病方面的重大未满足需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.097182},{"month":3,"riseRate":0.6,"avgChangeRate":0.026866},{"month":4,"riseRate":0.2,"avgChangeRate":-0.112596},{"month":5,"riseRate":0.4,"avgChangeRate":0.086858},{"month":6,"riseRate":0.8,"avgChangeRate":0.175967},{"month":7,"riseRate":0.6,"avgChangeRate":0.073307},{"month":8,"riseRate":0.6,"avgChangeRate":0.090179},{"month":9,"riseRate":0.4,"avgChangeRate":-0.166769},{"month":10,"riseRate":0.6,"avgChangeRate":0.061028},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MoonLake Immunotherapeutics(MLTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MoonLake Immunotherapeutics(MLTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}